Disease relevance of VERALIPRIDE

• Tardive blepharospasm beginning after withdrawal of veralipride [1].
• CONCLUSION: Veralipride reduced vasomotor symptoms induced by a GnRH-a. Transient hyperprolactinemia was the main side effect observed [2].
• Therefore, this is the first case reporting on veralipride unmasking a silent pheochromocytoma [3].
• Tardive dyskinesia after long-term veralipride treatment [4].
• In recent years, extrapyramidal disorders associated with veralipride therapy have been reported and are often due to drug misuse [5].

Psychiatry related information on VERALIPRIDE

• To the best of our knowledge, this is the first case of veralipride-induced tardive dystonia, and the affective disorder might have predisposed our patient to the development of this tardive side effect [6].

High impact information on VERALIPRIDE

• Serum PRL levels rose from 11.7 +/- 5.7 to 132.3 +/- 65.0 ng/mL (conversion factor to SI unit, 1.0) during veralipride administration and returned to 10.6 +/- 3.7 ng/mL after drug withdrawal [2].
• The present double-blind study was conducted to test the efficacy of veralipride, a synthetic antidopaminergic molecule, in eliminating the symptoms of menopause in 50 patients [7].
• Pharmacokinetics of veralipride after chronic administration in humans [8].
• The administration of veralipride, a centrally acting dopaminergic type 2 (DA2) receptor antagonist, can decrease hot flushes and improve bone density in post-menopausal women (1) [3].
• As regards hormonal effects, veralipride, by virtue of its antidopaminergic action, raised prolactin levels [9].

Chemical compound and disease context of VERALIPRIDE

• METHODS: We searched systematically studies using tibolone, serotonin reuptake inhibitors, clonidine, veralipride, gabapentin, black cohosh and phytoestrogens in breast cancer patients [10].

Biological context of VERALIPRIDE

• Interaction between veralipride and the endogenous opioid system in the regulation of body temperature in postmenopausal women [11].
• The influence of endogenous opioid peptides on body thermoregulation has been studied in untreated postmenopausal women and in the same subjects after chronic administration of the antidopaminergic drug veralipride (200 mg/day for 20 days) [11].
• Veralipride, a synthetic benzamide derivative with antidopaminergic action, is effective in reducing the frequency and severity of hot flushes associated with menopausal hypoestrogenism, gaining interest as a non-hormonal treatment for climacteric flushing [5].

Anatomical context of VERALIPRIDE

• Evidence for a second site of absorption of veralipride in the human small intestine. Use of a new drug delivery telemetric shuttle [12].

Associations of VERALIPRIDE with other chemical compounds

• We evaluated the administration of raloxifene and veralipride in postmenopausal women with high osteoporosis risk and hot flushes in whom hormone replacement therapy (HRT) was contraindicated [13].
• A new telemetric shuttle was used to coadminister veralipride (CAS 66644-81-3) and veralipride-D3 in order to test the assumption that veralipride is absorbed at two sites of the small intestine [12].

Gene context of VERALIPRIDE

• The frequency of both LH and PRL secretory pulses was not modified, while the mean pulse amplitude of both hormones was significantly increased (p less than 0.05 for LH; p less than 0.001 for PRL) by veralipride administration [14].
• Veralipride-induced tardive dystonia in a patient with bipolar psychosis [6].

Analytical, diagnostic and therapeutic context of VERALIPRIDE

• RESULTS: A satisfactory fit for hydromorphone and veralipride data following oral administration was achieved by fitting a sum of two or three IG functions [15].
• Quantitative analysis of veralipride in plasma and urine by gas chromatography-mass spectrometry and gas chromatography with flame-ionization detection [16].
• Equal doses of veralipride have been given to 12 healthy volunteers by three different administrations--intravenous infusion, oral solution, and oral capsules--in a randomized cross-over design [17].

References